[1]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72-74.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(02):72-74.[doi:10.3969/j.issn.1671-7414.2017.02.019]
点击复制

抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年02期
页码:
72-74
栏目:
论著
出版日期:
2017-03-25

文章信息/Info

Title:
Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples
文章编号:
1671-7414(2017)02-072-03
作者:
阮瑞杨1; 陈修荣2; 赵世元3
1.广西隆安县妇幼保健院,广西隆安 532799;
2.广西食品药品监督管理局,南宁 530029;
3.广西医科大学附属民族医院,南宁530001
Author(s):
RUAN Rui-yang1; CHEN Xiu-rong2; ZHAO Shi-yuan3
1.Longan County Maternal and Child Health Hospital,Guangxi Longan 532799,China;
2.Guangxi Food and Drug Administration,Nanning 530029,China;
3.the Affiliated National Hospital of Guangxi Medical University,Guangxi Nanning 530001,China
关键词:
肝细胞癌;  抗EZH2自身抗体IgG;  转移
分类号:
R735.7; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.02.019
文献标志码:
A
摘要:
目的 探讨肝癌患者血清中抗EZH2自身抗体IgG的表达与临床病理参数的关系和意义。方法 采用ELISA法检测120例肝癌患者血清中的抗EZH2自身抗体IgG抗体并与115例健康对照组比较。结果 肝癌组患者血清抗EZH2自身抗体IgG含量为2.015±0.568 μg/ml,健康对照组抗EZH2自身抗体IgG含量为1.185±0.289 μg/ml,两组比较差异有统计学意义(t=12.48,P<0.001); 肝癌患者血清抗EZH2自身抗体IgG的上调表达程度与肿瘤大小、肿瘤分化程度、TNM分级和肝内转移相关(t=8.485～57.93,P<0.001); 与年龄、性别、饮酒和HBV是否感染等无明显差异(t=1.22～5.20,P>0.05)。结论 血清抗EZH2自身抗体IgG表达上调与肝癌的发生发展相关,检测肝癌血清抗EZH2自身抗体IgG可能有利于判断肝癌的恶性行为以及预后评估有参考价值。
Abstract:
Objective To detect the anti EZH2 autoantibodies IgG expression in hepatocellular carcinoma patient's serum samples and investigate the relationship of anti EZH2 autoantibodies IgG expression with clinicopathological parameters.Methods ELISA method was used todetect the anti EZH2 autoantibodies in serum of 120 cases of HCC patients and compared with 115 healthy controls.Results Serum anti EZH2antibodies in patients with hepatocellular carcinoma group the content of IgG was 2.015±0.568 μg/ml group,anti EZH2 antibodies IgG content control healthwas 1.185±0.289 μg/ml.There was significant difference between two groups(t=12.48,P<0.001).Anti EZH2 antibodies of IgG in serum of patients with hepatocellular carcinoma was up-regulated and the degree of tumor size,tumor the degree of differentiation,TNM grading and intrahepatic metastasis(t=8.485～57.93,P<0.001).And age,sex,drinking,whether HBV infection had no significant difference(t=1.22～5.20,P>0.05).Conclusion The expression of anti EZH2 autoantibodies in serum was related to the occurrence and development of hepatocellular carcinoma,and the detection of serum anti EZH2 autoantibodies in serum of liver cancer may be helpful to judge the malignant behavior and prognosis of hepatocellular carcinoma(HCC),which may be used as a reference for the evaluation of the prognosis of HCC patients with IgG antibody against IgG.

参考文献/References:

[1] Bae WK,Hennighausen L.Canonical and non-canonical roles of thehistone methyltransferase EZH2 in mammary development and cancer[J].Mol CellEndocrinol,2014,382(1):593-597.
[2] Knutson SK,Warholic NM,Wigle TJ,et al.Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2[J].Proceedings of the National Academy of Sciences of the United States of America,2013,110(19):7922-7927.
[3] Roh SG,Park SY,Ko HS,et al.EZH2 expression in invasive lobular carcinoma of the breast[J].World J Surg Oncol,2013(11):299.
[4] Bracken AP,Pasini D,Capra M,et al.EZH2 is downstream of the pRB-E2Fpathway,essential for proliferation and amplified in cancer[J].EMBO J,2003,22(20):5323-5335.
[5] Granit RZ,Gabai Y,Hadar T,et al.EZH2 promotes a bilineage identity inbasal-like breast cancer cells[J].Oncogene,2013,32(33):3886-3895.
[6] 张利方,付丽萍,徐 娟,等.自身抗体在肝病患者诊断中的意义[J].现代检验医学杂志,2006,21(2):70-72. Zhang LF,Fu LP,Xu J,et al.Significance of auto-antibodies in diagnosis of liver disease[J].Journal of Modern Laboratory Medicine,2006,21(2):70-72.
[7] Sun NX,Ye C,Zhao Q,et al.Long noncoding RNA-EBIC promotes tumor cellinvasion by binding to EZH2 and repressing E-cadherin in cervical cancer[J].PLoS One,2014,9(7):e100340.
[8] Shen L,Cui J,Liang S,et al.Update of research on the role of EZH2 incancer progression[J].Onco Targets Ther,2013(6):321-324.
[9] 刘 冲,唐 浩,邓 霖,等.血清miRNA-186,miRNA-30c在肝细胞性癌中诊断价值的研究[J].现代检验医学杂志,2016,31(6):44-47. Liu C,Tang H,Deng L,et al.Research of diagnostic application ofserum miRNA-186 and miRNA-30c in patients with hepatocellular carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(6):44-47.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(02):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(02):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[4]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[5]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(02):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[6]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(02):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[7]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(02):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[8]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(02):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[9]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(02):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
[10]吴翠婷,周雪辉,张婉馨.基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1 抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J].现代检验医学杂志,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]
　WU Cuiting,ZHOU Xuehui,ZHANG Wanxin.Differential Expression of Glycolysis-related Genes in Patients with Advanced Hepatocellular Carcinoma Treated with PD-1 Inhibitors Screened Based on Biological Information Analysis, and Survival Benefit Model Constructed and Verified[J].Journal of Modern Laboratory Medicine,2023,38(02):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]

备注/Memo

备注/Memo:
基金项目:广西医疗卫生科研课题项目(Z2015066)。
作者简介:阮瑞杨(1968-),男,本科,主管检验师,主要从事医学检验工作及研究,Tel:13517672796,E-mail:gxlarry@163.com。
通讯作者:赵世元(1965-),男,主任技师,主要从事药物开发研究,Tel:13397812726,E-mail:zhaoshiyuan_1105@163.com。
更新日期/Last Update: 2017-04-10